Objectives. Information is presented concerning glycine transporters (GlyT) and possibilities of modulating their function in order to attain beneficial clinical effects.
Background. Glycine, a co-agonist of the glutamatergic NMDA receptor, was found to have a beneficial effect on negative and cognitive symptoms in patients with schizophrenia. Further substances are presently sought that would have a wider spectrum of action and more pronounced therapeutic effects than glycine. Sarcosine and its derivatives, as well as the so-called second generation GlyT inhibitors with a different chemical structure seem to be at present the most promising drugs.